Company intelligence / Profile preview

Oncology Newco

South San Francisco, California, United Statesexelixis.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Oncology Newco was created by bluebird bio to focus on oncology assets—primarily gene and cell therapies such as CAR-T targeting BCMA for multiple myeloma. Its lead program aimed for commercial launch with additional pipeline candidates advancing through clinical development. The company intended to deliver 1–2 new INDs per year starting in 2021–2022 using a proprietary product cycling platform.

Therapeutic areas: OncologyHematology
Modalities: Gene therapyCell therapy (notably CAR-T cell therapies)
Industry: Biotech

Drug pipeline

3 assets

BBO-8520

Phase 1

Indications: KRAS G12C-mutated non-small cell lung cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Oncology Newco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncology Newco.

Explore the full profile